AGP Picks
View all

Fresh news on health and wellness in Washington, D.C.

Provided by AGP

Potomac Health News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Potomac Health News.

Press releases published on April 27, 2026

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Suja Life Announces Launch of Initial Public Offering
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Sagimet Biosciences Provides Strategic and Corporate Updates
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Share us

on your social networks:

Sign up for:

Potomac Health News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.